Skip to main content
OpenTrials
Completed

NCT Number: NCT06463093

Differential Diagnosis of Cognitive Disorders of Psychiatric or Neurodegenerative Origin

The aim of the research is to analyze whether 18F-FDG PET helps in the diagnosis and therefore in the management of the patient.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Nancy's hospital

Vandœuvre-lès-Nancy, 54511, France

About this study

Neurocognitive disorder or Mild Cognitive Impairment corresponds to a decline in one or more cognitive functions; compared to the previous level of performance.

Indeed, the prevalence of neurodegenerative pathologies is estimated at more than one million according to Santé Publique France, due to the aging of the population. To be compared with the prevalence of the population suffering from a psychiatric disorder estimated at one in five people, or 13 million French people, in 2021.

With the increase in the prevalence of these two entities and their clinical entanglement, the question arises of the origin of neurocognitive disorders, is it a manifestation of a psychiatric pathology or a neurodegenerative pathology not yet diagnosed.

If this is the case, the patient's prognosis is modified with a pejorative evolution and a loss of autonomy which is to be anticipated. This delay deprives the patient and his family of interventions likely to alleviate behavioral disorders; maintain a level of autonomy compatible with life at home; alleviates the burden and improves the quality of life of caregivers.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult patients with cognitive impairment
  • Positron emission tomography with flurodeoxyglucose labeled with fluorine 18 carried out in the course of care

Exclusion criteria

  • Patients objecting to the collection of their data

Treatment and study plan

Primary outcomes

  1. Neuro cognitive disorders and disorders of neurodegenerative origin in psychiatric population

    Time frame: one day

    Change of the diagnosis before the PET and after the PET

Sponsors and collaborators

Lead sponsor

Central Hospital, Nancy, France

Other

Registry information

Official study title

Contribution of Brain Positon Emission Tomography With 18 Flurodeoxyglucose Labelled With Fluorine 18 for the Differential Diagnosis of Cognitive Disorders of Psychiatric or Neurodegenerative Origin

Acronym: ATEPDIPSY

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Jun 17, 2024
Registry last updated
Jun 25, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.